Jung-Yoon Choe1, Seong-Kyu Kim2. 1. Division of Rheumatology, Department of Internal Medicine, Arthritis and Autoimmunity Research Center, Catholic University of Daegu School of Medicine, 33, Duryugongwon-ro 17-gil, Nam-gu, Daegu, 705-718, Republic of Korea. 2. Division of Rheumatology, Department of Internal Medicine, Arthritis and Autoimmunity Research Center, Catholic University of Daegu School of Medicine, 33, Duryugongwon-ro 17-gil, Nam-gu, Daegu, 705-718, Republic of Korea. kimsk714@cu.ac.kr.
Abstract
OBJECTIVE: This study aimed to identify serum and urine biomarkers that correlate with disease activity in female patients with systemic lupus erythematosus (SLE). METHODS: Serum and urine levels of interferon γ-induced protein-10 (IP-10), TNF-like weak inducer of apoptosis (TWEAK), and monocyte chemotactic protein-1 (MCP-1) of 70 patients with SLE and 61 healthy controls were measured with enzyme-linked immunosorbent assays. RESULTS: The serum and urine levels of TWEAK, IP-10, and MCP-1 in both high and low SLE disease activity index (SLEDAI) groups of SLE patients were markedly higher compared with those of healthy controls. Moreover, the serum TWEAK level was positively correlated with the serum IP and serum MCP-1 levels (p < 0.001 for both). The serum TWEAK levels, SLEDAI scores, and urine protein/creatinine levels were significantly different between the SLE group with non-renal involvement and with renal involvement (p = 0.034, p < 0.001, and p < 0.001, respectively). The serum TWEAK level was a crucial determinant for a high SLEDAI score and renal involvement (p = 0.044 and p = 0.046, respectively). CONCLUSION: Serum TWEAK might be a serologic biomarker candidate that reflects disease activity and renal involvement in patients with SLE.
OBJECTIVE: This study aimed to identify serum and urine biomarkers that correlate with disease activity in female patients with systemic lupus erythematosus (SLE). METHODS: Serum and urine levels of interferon γ-induced protein-10 (IP-10), TNF-like weak inducer of apoptosis (TWEAK), and monocyte chemotactic protein-1 (MCP-1) of 70 patients with SLE and 61 healthy controls were measured with enzyme-linked immunosorbent assays. RESULTS: The serum and urine levels of TWEAK, IP-10, and MCP-1 in both high and low SLE disease activity index (SLEDAI) groups of SLEpatients were markedly higher compared with those of healthy controls. Moreover, the serum TWEAK level was positively correlated with the serum IP and serum MCP-1 levels (p < 0.001 for both). The serum TWEAK levels, SLEDAI scores, and urine protein/creatinine levels were significantly different between the SLE group with non-renal involvement and with renal involvement (p = 0.034, p < 0.001, and p < 0.001, respectively). The serum TWEAK level was a crucial determinant for a high SLEDAI score and renal involvement (p = 0.044 and p = 0.046, respectively). CONCLUSION: Serum TWEAK might be a serologic biomarker candidate that reflects disease activity and renal involvement in patients with SLE.
Authors: Brad H Rovin; Huijuan Song; Dan J Birmingham; Lee A Hebert; Chack Yung Yu; Haikady N Nagaraja Journal: J Am Soc Nephrol Date: 2004-12-15 Impact factor: 10.121
Authors: Y Avihingsanon; P Phumesin; T Benjachat; S Akkasilpa; V Kittikowit; K Praditpornsilpa; J Wongpiyabavorn; S Eiam-Ong; T Hemachudha; K Tungsanga; N Hirankarn Journal: Kidney Int Date: 2006-02 Impact factor: 10.612
Authors: Juliana de Andrade Rebouças Guimarães; Silvania da Conceição Furtado; Ana Cyra Dos Santos Lucas; Bruno Mori; José Fernando Marques Barcellos Journal: PLoS One Date: 2022-10-10 Impact factor: 3.752
Authors: Adrian Cordido; Laura Nuñez-Gonzalez; Julio M Martinez-Moreno; Olaya Lamas-Gonzalez; Laura Rodriguez-Osorio; Maria Vanessa Perez-Gomez; Diego Martin-Sanchez; Patricia Outeda; Marco Chiaravalli; Terry Watnick; Alessandra Boletta; Candido Diaz; Angel Carracedo; Ana B Sanz; Alberto Ortiz; Miguel A Garcia-Gonzalez Journal: J Am Soc Nephrol Date: 2021-06-21 Impact factor: 14.978
Authors: Anna Petrackova; Andrea Smrzova; Petr Gajdos; Marketa Schubertova; Petra Schneiderova; Pavel Kromer; Vaclav Snasel; Martina Skacelova; Frantisek Mrazek; Josef Zadrazil; Pavel Horak; Eva Kriegova Journal: Clin Proteomics Date: 2017-10-03 Impact factor: 3.988